Drisapersen
- Generic Name
- Drisapersen
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1251830-50-8
- Unique Ingredient Identifier
- 73D586DAMF
- Associated Conditions
- -
- Associated Therapies
- -
Extension Study of Drisapersen in DMD Subjects
- Conditions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- BioMarin Pharmaceutical
- Registration Number
- NCT02636686
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Afdeling Neurologie, Gent, Belgium
🇧🇪Queen Fabiola Children's University Hospital, Brussels, Belgium
🇯🇵National Hospital Organization, Saitama, Japan
A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 12
- Registration Number
- NCT01910649
Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2014-03-24
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01890798
A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 53
- Registration Number
- NCT01803412
- Locations
- 🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath